Veracyte Announces Global Expansion Plans with NanoString nCounter® Platform     Learn More
Veracyte Announces Global Expansion Plans with NanoString nCounter® Platform     Learn More
Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides 2020 Financial Outlook
2019 Total Revenue Grew 31% to $120.4 Million ; Genomic Test Volume Grew 25% to 39,612 Achieved Fourth Quarter 2019 Positive Cash Flow from Operations Fourth Quarter Acquisition Positions Company for Global Expansion Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Veracyte to Present at the 9th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 13, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 27,
View HTML

Events

There are currently no events to display.

Presentations

Title Documents

Corporate Presentation February 2020